Table 2 Baseline characteristics of patients in the COMBI-v and coBRIM studies
| Â | COMBI-v | coBRIM | ||
|---|---|---|---|---|
D + T | V | V + placebo | V + C | |
Intent-to-treat population | 352 | 352 | 248 | 247 |
Age, median (range), yr | 55(18–91) | 54(18–88) | 55(25–85) | 56(23–88) |
Male sex, no. (%) | 208(59) | 180(51) | 140(56) | 146(59) |
ECOG score, no./total no. (%) | ||||
 0 | 248/350(71) | 248/352(70) | 164/244(67) | 184/243(76) |
 1 | 102/350(29) | 14/352(30) | 80/244(33) | 58/243(24) |
 2 | 0/350 | 0/352 | 0/244 | 1/243(<1) |
Metastatic status, no./total no. (%) | ||||
 M0 | 14/351(4) | 26/351(7) | 13(5) | 21(9) |
 M1a | 55/351(16) | 50/351(14) | 40(16) | 40(16) |
 M1b | 61/351(17) | 67/351(19) | 42(17) | 40(16) |
 M1c | 221/351(63) | 208/351(59) | 153(62) | 146(59) |
Elevated LDH, no. /total no. (%) | 118/351(34) | 114/352(32) | 104/242(43) | 112/242(46) |
BRAF mutation, no. /total no. (%) | ||||
 V600E | 312/346(90) | 317/351(90) | 174/206(84) | 170/194(88) |
 V600K | 34/346(10) | 34 /351(10) | 32/206(16) | 24/194(12) |